Late-gadolinium enhancement predicts appropriate device therapies in nonischemic recipients of primary prevention implantable cardioverter-defibrillators.

ABSTRACT:

Background

Better risk stratification is needed to evaluate patients with nonischemic cardiomyopathy (NICM) for prophylactic implantable cardioverter-defibrillators (ICDs). Growing evidence suggests that cardiac magnetic resonance (CMR) imaging may be useful in this regard.

Objective

We aimed to determine if late gadolinium enhancement (LGE) seen on CMR (dichotomized as none or minimal <2% vs significant ≥2%) predicts appropriate ICD therapies (primary endpoint) or all-cause mortality/transplant/left-ventricular assist device (LVAD) implantation (secondary endpoint) in patients with NICM.

Methods

We identified 344 patients with NICM who underwent primary prevention ICD implantation at Cleveland Clinic between 2003 and 2021 with CMR within 12 months before implant. LGE

SUBMITTER: Kiang A 

PROVIDER: S-EPMC12241459 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature